Long‐Term Follow‐Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease
Movement Disorders · 2024
DOI: 10.1002/mds.29796 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, 2024. Verfasst von Henrieke L Frequin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Amsterdam University Medical Centers, Amsterdam Neuroscience, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Antiparkinson Agents, Carbidopa. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ZonMw, Stichting ParkinsonFonds, Parkinson Vereniging.
Abstract (Originalsprache)
Background and Objective The Levodopa in EArly Parkinson's disease study showed no effect of earlier versus later levodopa initiation on Parkinson's disease (PD) progression over 80 weeks. We now report the effects over 5 years.
Methods
The Levodopa in EArly Parkinson's disease study randomly assigned patients to levodopa/carbidopa 300/75 mg daily for 80 weeks (early start) or to placebo for 40 weeks followed by levodopa/carbidopa 300/75 mg daily for 40 weeks (delayed start). Follow‐up visits were performed 3 and 5 years after baseline. We assessed the between‐group differences in terms of square root transformed total Unified Parkinson's Disease Rating Scale score at 3 and 5 years with linear regression. We compared the prevalence of dyskinesia, prevalence of wearing off, and the levodopa equivalent daily dose.
Results
A total of 321 patients completed the 5‐year visit. The adjusted square root transformed total Unified Parkinson's Disease Rating Scale did not differ between treatment groups at 3 (estimated difference, 0.17; standard error, 0.13; P = 0.18) and 5 years (estimated difference, 0.24; standard error, 0.13; P = 0.07). At 5 years, 46 of 160 patients in the early‐start group and 62 of 161 patients in the delayed‐start group experienced dyskinesia ( P = 0.06). The prevalence of wearing off and the levodopa equivalent daily dose were not significantly different between groups.
Conclusions
We did not find a difference in disease progression or in prevalence of motor complications between patients with early PD starting treatment with a low dose of levodopa 40 weeks earlier versus 40 weeks later over the subsequent 5 years. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Amsterdam University Medical Centers, Amsterdam Neuroscience, Amsterdam, the Netherlands.
- Department of Medical Psychology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
- Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Center of Expertise for Parkinson & Movement Disorders, Nijmegen, the Netherlands.
- Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Neurology, Zuyderland Medical Center, Heerlen, the Netherlands.
ORCID-Profile: Henrieke L Frequin, Teus van Laar, Anthony E Lang, Rob M A de Bie
Förderung
- ZonMw
- Stichting ParkinsonFonds
- Parkinson Vereniging
- Stichting Parkinson Nederland
Zitieren
APA
Frequin, H. L., Verschuur, C. V. M., Suwijn, S. R., Boel, J. A., Post, B., Bloem, B. R., van Hilten, J. J., van Laar, T., Tissingh, G., Munts, A. G., Dijk, J. M., Lang, A. E., Dijkgraaf, M. G. W., Hoogland, J., de Bie, R. M. A., & LEAP Study Group (2024). Long‐Term Follow‐Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease. Movement Disorders. https://doi.org/10.1002/mds.29796
Vancouver
Frequin HL, Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, et al. Long‐Term Follow‐Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease. Movement Disorders. 2024. doi:10.1002/mds.29796
BibTeX
@article{Frequin2024,
author = {Frequin, Henrieke L and Verschuur, Constant V M and Suwijn, Sven R and Boel, Judith A and Post, Bart and Bloem, Bastiaan R and van Hilten, Johannes J and van Laar, Teus and Tissingh, Gerrit and Munts, Alexander G and Dijk, Joke M and Lang, Anthony E and Dijkgraaf, Marcel G W and Hoogland, Jeroen and de Bie, Rob M A and LEAP Study Group, LEAP Study Group},
title = {Long‐Term Follow‐Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease},
journal = {Movement Disorders},
year = {2024},
doi = {10.1002/mds.29796}
}
EUVIMED